$TEM EXECUTIVE TAKEAWAYS
• Tempus reported record Total Remaining Contract Value (TCV) of >$1.1 billion as of 12/31/2025, alongside preliminary, unaudited 2025 Data and application revenue of ~$316 million (+~31% year-over-year) and net revenue retention of ~126% (Insights cohort basis).
• TCV, as defined by Tempus, is structurally an upper-bound measure of contracted potential: it assumes 100% exercise of contractual options and discretionary opt-ins and assumes no early termination; it also excludes revenue already recognized and excludes future contractual value changes from amendments or terminations. This framing supports “visibility” narratives but reduces conservatism versus traditional backlog or RPO measures.
• Year-over-year TCV expansion is directionally supportive of demand, but the quality of that signal depends on (1) the mix of firm commitments versus optionality embedded in TCV and (2) conversion kinetics into recognized revenue and cash. Tempus’ own SEC disclosure explicitly flags termination-for-convenience risk and uncertainty around option/opt-in exercise.
• Customer count breadth (data agreements with >70 customers in 2025, including multiple large pharmas) indicates commercial penetration; however, economic concentration may still be meaningful, given the common structure of multi-year “strategic collaborations” and the historical disclosure that 1 customer represented 8.3% of annual revenue in both 2022 and 2023.
EVENT SUMMARY AND WHAT WAS ANNOUNCED
Tempus announced that Total Contract Value (defined in the release as Total Remaining Contract Value, TCV) exceeded $1.1 billion as of 12/31/2025, described as the highest level in company history. The same release disclosed preliminary, unaudited 2025 Data and application revenue of ~$316 million (+~31% year-over-year), with Insights (data licensing) growing 38%, and stated 2025 net revenue retention of ~126% (Insights cohort definition). Tempus stated that >70 data agreements were signed during 2025 across large and mid-sized pharma and biotech, and listed representative counterparties including AstraZeneca, GlaxoSmithKline, Bristol Myers Squibb, Pfizer, Novartis, Merck, Abbvie, Daiichi Sankyo, Eli Lilly, Boehringer Ingelheim, Incyte, Servier, Aspera Biomedicines, and Whitehawk Therapeutics. The release emphasized that figures were preliminary and unaudited, with final results to be reported during an earnings call in February 2026.
DEFINITIONS, NON-GAAP NATURE, AND MEASUREMENT RISK
Tempus defines TCV as the total potential value of signed contracts, explicitly assuming (1) exercise of all contract options, (2) exercise of all discretionary opt-ins, and (3) no early termination; it excludes revenue already recognized and excludes future adjustments to contractual value from amendments or terminations. Net Revenue Retention is defined as a cohort metric comparing annual Insights revenue from customers who made an Insights purchase in a given year to the revenue from the same cohort in the subsequent year. These definitions are important because they structurally bias TCV upward relative to measures that include only enforceable minimum commitments, and they separate TCV from GAAP concepts such as revenue, deferred revenue, and remaining performance obligations. Tempus’ S-1 disclosure adds multiple caveats: contracts may include termination clauses (including termination for convenience); there is no guarantee that options or discretionary opt-ins will be exercised or that full potential revenue will be realized; Remaining TCV is not a revenue calculation or a forecast; and the metric may not be comparable across companies. In aggregate, the definition and caveats imply that TCV should be interpreted as a “contracted potential ceiling” rather than a conservative backlog floor, and therefore should be discounted when translating into forward revenue or cash expectations.
A further nuance in Tempus’ SEC disclosure is that Remaining TCV includes the total potential value of strategic collaborations with AstraZeneca and GSK that, while listed under the Data and Services product line, could be satisfied by the purchase of any Tempus products and services. This matters for analytical mapping because it weakens the direct linkage between a “data-only” contracting metric and the future segment revenue line item labeled Data and applications (or historically Data and services). It also increases the importance of understanding contract-level performance obligations, allocation of transaction price across deliverables, and the extent to which a given strategic collaboration can shift revenue across segments or products based on customer elections.
HISTORICAL CONTEXT: TCV AND RETENTION TRENDLINE
Tempus disclosed Remaining TCV of >$920.0 million as of 12/31/2023 (including approximately $300.0 million in additional potential future contractual opt-ins) in its SEC registration statement. Tempus then reported that it ended 2024 with $940 million in Total Remaining Contract Value and 140% net revenue retention, alongside 2024 Data and services revenue of $241.6 million. The newly disclosed >$1.1 billion TCV as of 12/31/2025 therefore implies at least a ~17% year-over-year increase versus the 12/31/2024 TCV level (noting both figures are described as “more than” or rounded, limiting precision). Over a 2-year window, the movement from >$920 million (12/31/2023) to >$1.1 billion (12/31/2025) indicates continued net growth in contracted potential, but the incremental slope appears more pronounced in 2025 than 2024 if the rounded disclosures are taken at face value. In parallel, net revenue retention declined from 140% (2024) to ~126% (2025), a 14 percentage-point step-down. This pattern is consistent with multiple benign explanations (larger base dampening percentage expansion, normalization after very large expansions, cohort composition changes), but it also removes some upside convexity that 140% retention implies and increases the need to underwrite new customer additions and new product attach for sustained >30% segment growth.
COMMERCIAL SIGNALS EMBEDDED IN “>$1.1 BILLION TCV”
The TCV level is economically meaningful relative to the segment’s annual revenue scale. Using the disclosed ~$316 million 2025 Data and application revenue, >$1.1 billion of remaining TCV implies a remaining contracted-potential coverage ratio of >3.5x annual segment revenue at the 2025 run-rate. This ratio can be directionally supportive for multi-year visibility narratives, but it cannot be treated as a deterministic revenue schedule because (1) TCV assumes 100% option/opt-in exercise and 0% early termination and (2) revenue recognition depends on when performance obligations are satisfied and how consideration is allocated across deliverables.
A second way to frame the commercial signal is to infer an “implied bookings” magnitude. If (for analytical purposes only) TCV is assumed to apply to the same underlying contracting base that generates the Data and application revenue line, then moving from $940 million TCV at 12/31/2024 to >$1.1 billion at 12/31/2025, while recognizing ~$316 million of 2025 segment revenue, implies net additions to Remaining TCV during 2025 of >$476 million (calculated as Ending TCV – Beginning TCV + Annual Segment Revenue, with simplifying assumptions around scope consistency and excluding terminations/amendments). This inference suggests that 2025 contracting activity likely exceeded recognized revenue by a wide margin, consistent with a scaling commercial motion in data licensing and related products. However, because TCV itself embeds option/opt-in assumptions, this inferred bookings figure should be viewed as an upper-bound proxy rather than a conservative, GAAP-aligned bookings estimate.
The disclosed count of >70 data agreements signed in 2025 reinforces breadth. The counterparty list spans multiple large-cap pharmas as well as smaller biotechs, suggesting demand is not narrowly confined to 1 therapeutic area sponsor or 1 deal type. The disclosed net revenue retention of ~126% further suggests existing customers expanded spend year-over-year on the Insights product set, supporting a “land-and-expand” dynamic. The deceleration versus the 2024 140% level, however, increases the importance of distinguishing whether incremental growth is coming from (1) deeper penetration within a stable set of large customers, (2) new customer adds, or (3) expansion of SKU breadth (data licensing plus model development plus clinical development tools) within existing accounts.
REVENUE RECOGNITION, QUARTERLY MIX, AND COMPARABILITY NOISE
Tempus’ disclosure accompanying the TCV release emphasizes that the revenue figure is preliminary, unaudited, and subject to potentially material change. This caveat is non-trivial in a year that includes acquisitions and complex non-cash accounting items, because finalization of purchase accounting, valuation marks, and revenue recognition judgments can move reported segment revenue and margins.
The separate preliminary 2025 results release provides additional texture on quarterly mix and an explicit callout of comparability distortions: Q4 2025 Data and applications revenue was disclosed as ~$100 million (+~25% year-over-year), while Insights grew ~68% excluding the impact of the AstraZeneca warrant in Q4 2024. The combination of (1) a Q4 segment growth rate materially below the Insights growth rate and (2) an explicit “excluding warrant impact” adjustment implies that non-Insights components of the segment were either growing slower, declining, or experiencing timing-related lumpiness, and that at least part of the 2024 baseline was distorted by non-cash warrant-related accounting. This reinforces the need to separate structural demand (contracting and renewal) from accounting presentation when underwriting growth persistence.
The AstraZeneca warrant accounting is described in Tempus’ SEC disclosure. In Q4 2021, in conjunction with signing a November 2021 master services agreement with AstraZeneca AB, Tempus recognized a contract asset for consideration payable concurrent with issuing a common stock warrant under ASC 606, with initial measurement tied to the warrant liability’s fair value under ASC 718. As revenue is recognized over the period of the contractual commitment, associated contract asset amortization is recorded as a reduction of revenue. This mechanism can create material “noise” in reported revenue growth depending on the size and timing of amortization (and, separately, fair value changes in the warrant liability affecting non-operating income). The 2025 preliminary results release’s explicit reference to excluding the AstraZeneca warrant impact in Q4 2024 is consistent with this being a meaningful swing factor for year-over-year comparability in the data licensing line.
STRATEGIC DEAL STRUCTURE AND HOW IT FEEDS TCV
A significant contributor to the scale and credibility of Tempus’ data business is the presence of large, multi-year strategic collaborations with major pharmas. In April 2025, Tempus announced multi-year strategic collaborations with AstraZeneca and Pathos to build a multimodal foundation model in oncology, with agreements including $200 million in data licensing and model development fees payable to Tempus. This magnitude is material relative to 2025 Data and application revenue (~$316 million) and is directionally consistent with Tempus’ narrative that an increasing number of biopharma companies are incorporating Tempus’ multimodal dataset into drug discovery and development workflows. Such deals can pull through both (1) near-term revenue via data licensing/model development and (2) multi-year TCV expansion via embedded options, opt-ins, and extensions.
The structure of the GSK relationship provides a concrete example of how contractual minimums and extensions can shape TCV. GSK disclosed in October 2022 that it entered into a 3-year collaboration agreement with Tempus providing access to Tempus’ AI-enabled platform and de-identified patient data library, with a minimum financial commitment over 3 years including a $70 million initial payment, and with an option to extend for 2 additional years. The presence of a minimum commitment plus extension optionality is precisely the type of structure that can inflate TCV relative to enforceable minimums when the metric assumes full exercise of options and opt-ins. Consequently, a rising TCV can reflect both (1) true incremental contracted demand and (2) mechanical inclusion of optional extensions and discretionary scope expansions, which may be exercised at rates that vary with pharma R&D budgets, competitive priorities, and realized value from prior work.
CUSTOMER CONCENTRATION AND COUNTERPARTY RISK
While the 2025 disclosure highlights >70 customer agreements, concentration should still be treated as a key underwriting variable. In Tempus’ SEC disclosure, 1 customer accounted for 8.3% of revenues in both 2022 and 2023, and an additional customer accounted for 5.1% of revenues in 2023 (while not significant in 2022). These levels indicate that a small number of customers can be economically meaningful even before considering the potential for large strategic collaborations to represent a disproportionate share of contracting value. The 2025 customer list includes several of the largest global pharmas, which can be credit-positive, but can also increase negotiation leverage, renewal friction, and the probability of shifting scope toward non-exclusive or internally developed alternatives over time.
ECONOMIC INTERPRETATION: WHAT “VISIBILITY” IS REALISTIC
From an economic standpoint, Remaining TCV should be interpreted as a reservoir of potential future monetization rather than a time-phased revenue schedule. The metric’s assumptions (100% option/opt-in exercise; 0% early termination) and Tempus’ disclosure that counterparties may terminate for convenience mean realized value will be lower than TCV in adverse cases and could be materially lower if renewal/extension optionality is not exercised. Conversely, the existence of a large TCV base can still be strategically valuable because it (1) indicates that procurement and contracting hurdles have been cleared, (2) creates a foundation for expansions and cross-sell, and (3) can support internal investment decisions (compute, R&D, and product expansion) with some confidence that demand exists at scale. The key analytical question is the conversion function: the rate at which TCV converts to recognized revenue and cash, net of churn and scope reductions, and net of incremental costs required to deliver data and model development obligations.
The disclosed net revenue retention of ~126% is supportive of conversion quality in the sense that existing Insights customers are, on average, expanding spend year-over-year. However, the downshift from 140% in 2024 suggests either (1) reduced expansion intensity, (2) a smaller contribution from very large expansions, or (3) higher churn/downsells partially offsetting expansions. Without disclosure of gross retention, logo retention, cohort size, and distribution (e.g., median vs mean expansion), it remains unclear whether 126% reflects a broad-based expansion motion or a small number of large accounts. This distinction is critical because a small number of large accounts would imply higher volatility in both NRR and TCV, even if the point-in-time metrics appear strong.
STRATEGIC POSITIONING AND COMPETITIVE DYNAMICS
The disclosed customer set and the presence of multi-year, high-dollar collaborations suggest that Tempus is being positioned not merely as a diagnostics vendor but as a scaled data and AI enablement platform for life sciences R&D. The AstraZeneca/Pathos collaboration explicitly ties Tempus’ de-identified oncology data to foundation model development and assigns a $200 million fee pool to data licensing and model development. The GSK disclosure highlights use cases spanning clinical trial design, enrollment, and target identification and references Tempus’ access to de-identified data drawn from work with >40% of oncologists in the U.S. at academic medical centers and community hospitals. These disclosures collectively support an investment narrative that the data asset and associated tooling are being monetized at increasing scale, and that “model-building” is emerging as a packaged commercial deliverable, not just an internal capability.
At the same time, the competitive environment for real-world data, clinico-genomic datasets, and AI-enabled trial optimization remains structurally competitive, with credible alternatives spanning EHR-native RWD aggregators, oncology-specific clinical data networks, and sequencing-led competitors with their own data moats. The sustainability of pricing and renewal rates will depend on data differentiation (modality breadth, longitudinal outcomes linkage, data quality/cleanliness, representativeness, and timeliness) and on productization (how easily partners can operationalize the dataset and models into repeatable R&D workflows). TCV growth is consistent with differentiation, but it does not prove durability; durability is better evidenced by multi-year renewals exercised without pricing compression, stable-to-improving gross retention, and expanding wallet share across an increasing number of customers.
KEY RISKS AND UNDERWRITING CONSIDERATIONS
• TCV inflation risk: TCV assumes full option and opt-in exercise and no early termination; Tempus explicitly discloses that there is no guarantee these assumptions will hold and that counterparties may terminate for convenience.
• Segment mapping ambiguity: Remaining TCV includes strategic collaborations (AstraZeneca and GSK) that can be satisfied by purchases across Tempus products and services, weakening direct mapping from “data TCV” to a single reported segment line.
• Accounting-driven volatility: The AstraZeneca warrant structure creates non-cash revenue reductions via contract asset amortization and can distort growth comparisons; the company itself highlights warrant impact when describing Q4 2025 Insights growth.
• Customer concentration: Historical disclosures indicate meaningful revenue concentration in a small number of customers (8.3% revenue concentration in 2022 and 2023 for 1 customer). Large strategic collaborations, while validating, can further concentrate economics and increase renewal leverage asymmetry.
• Retention trajectory: Net revenue retention declined from 140% (2024) to ~126% (2025), which may reflect normalization but also may indicate slowing expansion momentum.
• Delivery and cost-to-serve risk: Multi-year model development and data platform commitments can carry meaningful compute, engineering, and governance costs; margin outcomes depend on efficient reuse/productization versus bespoke services delivery.
• Regulatory and privacy risk: Evolving rules around de-identification, secondary use of health data, and AI governance could affect dataset usability, contracting structure, and customer willingness to commit to multi-year optionality.
SPECIFIC INFORMATION GAPS TO RESOLVE AT THE FEBRUARY 2026 EARNINGS EVENT
1.TCV composition: breakdown of enforceable minimum commitments versus options/extensions versus discretionary opt-ins; historical exercise rates; and any known concentration (top 5 customers’ share of TCV).
2.TCV duration and conversion: weighted-average remaining contract term, expected annualization of remaining TCV, and reconciliation (even if non-GAAP) from beginning-of-period TCV to ending TCV showing bookings, revenue recognized, and churn/terminations/amendments.
https://t.co/QnzO7ThbW8 realization: cash collections cadence for large collaborations (upfront vs milestone vs ratable), deferred revenue and/or remaining performance obligations disclosures, and the relationship between TCV and near-term cash flow.
4.Segment mix and drivers: explanation for the divergence between Q4 segment growth (+~25%) and adjusted Insights growth (+~68% excluding warrant impact), including the trajectory of non-Insights “applications” revenue components.
5.Retention decomposition: gross retention, logo retention, expansion distribution (median vs mean), and cohort size to assess whether 126% NRR is broad-based or driven by a small number of accounts.
6.Warrant accounting forward profile: remaining period of AstraZeneca warrant contract asset amortization (revenue reduction), sensitivity to warrant liability fair value changes, and expected comparability impacts into 2026.
IMPLICATIONS FOR FUNDAMENTAL UNDERWRITING
The >$1.1 billion TCV disclosure is a constructive demand signal for Tempus’ life sciences data licensing and related applications, particularly when viewed alongside (1) ~31% annual growth in Data and application revenue to ~$316 million and (2) ~126% net revenue retention in Insights. The contracting breadth (>70 agreements in 2025 across large pharma and biotech) supports the view that Tempus’ multimodal dataset is increasingly being operationalized within drug discovery and development workflows.
However, the definitional structure of TCV requires disciplined discounting in valuation models. TCV assumes away key downside states (non-exercise of options/opt-ins and early termination) and includes strategic collaborations that may be satisfied through purchases across product lines, complicating mapping to segment revenue and margin. The most analytically rigorous interpretation is that TCV measures commercial footprint and potential monetization capacity rather than a binding revenue schedule. Under that interpretation, the TCV milestone primarily increases confidence in the existence of a scaled demand pool and in Tempus’ ability to secure multi-year contracting constructs, while leaving the magnitude and timing of realized economics contingent on execution, renewal behavior, and contract-specific revenue recognition.
In summary, the disclosure strengthens the “platform” narrative but does not, in isolation, resolve the key investment questions of (1) how much of TCV is truly committed, (2) how quickly and profitably it converts to recognized revenue and cash, and (3) how resilient net retention will be as the customer base scales and as very large strategic collaborations mature. The February 2026 earnings release is positioned as the primary catalyst for validating conversion, duration, and profitability dynamics behind the headline >$1.1 billion figure.I
